BioSpace News Archive

Of the 205 companies surveyed in ABI Research’s latest Location Technologies Supply Chain and Ecosystem Tracker, 24% of them are currently offering solutions covering both indoor and outdoor location services, according to ABI Research, a market-foresight advisory firm providing strategic guidance on the most compelling transformative technologies.

MaaT Pharma announced that the Institut National de la Propriété Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated with obtaining, processing, storing and administering human gut samples, ensuring that the highest quality of microbiota is present in MaaT Pharma’s biologic drugs.

Halozyme Therapeutics, Inc. announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.

Nuevolution AB announces its report for the first quarter of 2019.

Ascentage Pharma announced the presentation of new clinical data for its investigational apoptosis-targeted drug candidates at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago from May 31-June 4.

IDEAYA Biosciences, Inc. announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.

FDB MedKnowledge™ Canada, the most widely used drug database within healthcare IT applications, now includes additional clinician-facing content to fully support bi-lingual app development

Extensive Clinical Experience at Siteman Cancer Center Helps Further Adoption and Clinical Practice of MR-guided and On-Table Adaptive Radiation Therapy

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a presentation at TIDES: Oligonucleotide and Peptide Therapeutics, the world’s largest meeting to accelerate oligonucleotide and peptide products from early discovery to late-stage development and commercialization.

Liberty Health Sciences Inc. announced that Sheri Cholodofsky has been appointed Chief Financial Officer, subject to Florida Department of Health approval.